课题基金 / 基金详情

EVC2: A novel modulator in tooth development

EVC2: A novel modulator in tooth development
EVC2:牙齿发育的新型调节剂
批准号:
8074330
负责人:
YOSHIYUKI MOCHIDA
金额:
$37.1万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2014-06-30

项目摘要

项目成果

YOSHIYUKI MOCHIDA的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):Ellis-van Creveld (EVC)综合征是一种常染色体隐性软骨发育不良伴侏儒症。EVC患者的短唇被系带与肺泡嵴结合,也被描述为增生性系带伴浅唇沟,这是该综合征所特有的。他们也有一些主要的牙齿异常,包括新生儿牙齿,部分无牙畸形,钉状牙齿,恒牙延迟萌出和早期龋病。由于这些牙齿表现不是简单地由发育迟缓引起的,因此对这种特殊综合征的调查将为了解牙齿发育提供新的见解。现在很清楚,EVC综合征是由EVC或EVC2基因突变引起的,这两个基因都位于人类染色体4p上,呈头对头结构。在日本棕色牛中发现的牛软骨发育不良侏儒症(bcd)的致病基因LIMBIN后来被确定为EVC2的牛同源基因,这表明EVC2蛋白功能的重要性。为了研究EVC患者侏儒症/牙齿发育的病理生理机制,通过在EVC患者和bcd牛中发现的突变,在12外显子中引入一个过早停止密码子,产生Evc2突变小鼠。由于在EVC综合征中发现的大多数突变是无义突变,它们导致肽的过早终止,导致“功能丧失”。这些纯合突变小鼠表现出与EVC患者相似的严重侏儒症和牙齿异常,表明该疾病的潜在动物模型。在我们最初的表征中,我们在突变小鼠中发现了几种主要的牙齿表型。所有牙齿的牙釉质普遍发育不全。成年期切牙虽能连续生长,但长度较短,上切牙突牙不良(有时不突牙),方向不正常。胚胎第18.5天,成釉细胞分化明显受阻,缺乏细胞极化,没有明显的微管,淀粉原蛋白分泌不足,基质金属蛋白酶(MMP)-2表达改变。体外研究表明,野生型(WT) Evc2定位在成釉细胞系LS8的高尔基体上,而突变型Evc2“非”定位在细胞质上。此外,来自Evc2突变小鼠的小鼠胚胎成纤维细胞表现出较差的细胞迁移,与来自WT小鼠的细胞相比,这些细胞中的JNK磷酸化水平显着降低。这些初步数据使我们假设EVC2对成釉细胞微管的形成至关重要,这些微管在牙齿发育过程中控制细胞外基质(ECM)/MMP蛋白的运输和细胞迁移。为了检验这一假设,提出以下具体目标;Aim1。研究Evc2突变小鼠的牙齿发育特征。Aim2。探讨人EVC2突变对成釉细胞功能的影响。Aim3。通过EVC2突变挽救成釉细胞表型。本研究的数据将为EVC2在成釉细胞功能中的病理生理功能和牙齿发育的分子机制提供新的见解。
英文摘要
DESCRIPTION (provided by applicant): Ellis-van Creveld (EVC) syndrome is an autosomal recessive chondrodysplasia with dwarfism. The EVC patients have a short lip bound by frenum to alveolar ridge, which is also described as hyperplastic frena with a shallow labial sulcus, unique to this syndrome. They also have several major dental anomalies including neonatal teeth, partial anodontia, peg-shaped teeth, delayed eruption of permanent teeth and early involvement with caries. Since these dental manifestations are not simply caused by developmental delay, an investigation in this particular syndrome will provide a new insight into the understanding of tooth development. It is now clear that EVC syndrome is caused by mutations in either EVC or EVC2 gene, both of which are located on human chromosome 4p in a head-to-head configuration. A causative gene, LIMBIN for bovine chondrodysplastic dwarfism (bcd) found in Japanese brown cattle was later identified as the bovine ortholog of EVC2, indicating the significance of EVC2 protein function. In order to investigate the pathophysiological mechanism of dwarfism/tooth development seen in EVC patients, Evc2 mutant mice were generated by introducing a premature stop codon in exon12, mimicking mutations found in EVC patients and bcd cattle. As the majority of mutations identified in EVC syndrome are non-sense mutations, they result in premature termination of the peptide causing 'loss of function'. These homozygous mutant mice showed severe dwarfism with dental anomalies similar to EVC patients, indicating a potential animal model of this disease. During our initial characterization, we found several major dental phenotypes in the mutant mice. All teeth were generally hypoplastic in enamel formation. Although incisors were able to grow continuously, they were short in length and upper incisors were poorly erupted (sometimes not erupted) with abnormal direction at the adult stage. At embryonic day 18.5, differentiation of ameloblasts was clearly arrested lacking cell polarization with no apparent microtubules, poor amelogenin secretion and altered matrix metalloproteinase (MMP)-2 expression. The in vitro studies demonstrated that wild type (WT) Evc2 is localized at the Golgi in an ameloblastic cell line, LS8, whereas mutant Evc2 is "mis"localized at the cytoplasm. Moreover, mouse embryonic fibroblasts derived from the Evc2 mutant mouse exhibited poor cell migration and the level of JNK phosphorylation in these cells was markedly reduced when compared to those from WT mouse. These preliminary data led us to hypothesize that EVC2 is critical for the formation of microtubules of ameloblasts that control extracellular matrix (ECM)/MMP protein trafficking and cell migration during tooth development. In order to test this hypothesis, the following specific aims are proposed; Aim1. To characterize the tooth development in Evc2 mutant mice. Aim2. To investigate the effects of human EVC2 mutations on ameloblast cell function. Aim3. To rescue the ameloblast phenotypes by EVC2 mutation. The data obtained from this study will provide new insights into the pathophysiological function of EVC2 in ameloblast cell function and the molecular mechanism for tooth development. PUBLIC HEALTH RELEVANCE: People suffering from Ellis-van Creveld (EVC) syndrome show oral/dental abnormalities including missing/small teeth. In order to investigate the mechanism of dental abnormalities in EVC patients caused by a mutation in EVC2 gene, we have generated Evc2 mutant mice. The goal of our study is to determine when and how these mice develop abnormal teeth, to investigate the effect of Evc2 mutation on the cell movement in teeth, and to rescue the effect of Evc2 mutation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
EVC2: A novel modulator in tooth development
  • 批准号:
    8291133
  • 项目类别:
  • 资助金额:
    $39.29万
  • 财政年份:
    2009
  • 负责人:
    YOSHIYUKI MOCHIDA
  • 依托单位:
EVC2: A novel modulator in tooth development
Role of Vwc2-assisted activin signaling in bone formation
  • 批准号:
    7893658
  • 项目类别:
  • 资助金额:
    $18.1万
  • 财政年份:
    2009
  • 负责人:
    YOSHIYUKI MOCHIDA
  • 依托单位:
EVC2: A novel modulator in tooth development
  • 批准号:
    8495760
  • 项目类别:
  • 资助金额:
    $37.71万
  • 财政年份:
    2009
  • 负责人:
    YOSHIYUKI MOCHIDA
  • 依托单位:
国内基金
海外基金
Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    崔文晓
  • 依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    边兴博
  • 依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    刘亚
  • 依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
    32102747
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    李婉雁
  • 依托单位: